As vaccine technology continues to evolve, simply developing an effective antigen is no longer enough to achieve strong and lasting immune protection. Modern vaccine platforms—including recombinant proteins, peptide vaccines, subunit vaccines, and mRNA-based formulations—often face one common challenge: limited natural immunogenicity. To address this issue, advanced adjuvant...